Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity
Tóm tắt
The majority of chimeric antigen receptor (CAR) T-cell research has focused on attacking cancer cells. Here, we show that targeting the tumor-promoting, nontransformed stromal cells using CAR T cells may offer several advantages. We developed a retroviral CAR construct specific for the mouse fibroblast activation protein (FAP), comprising a single-chain Fv FAP [monoclonal antibody (mAb) 73.3] with the CD8α hinge and transmembrane regions, and the human CD3ζ and 4-1BB activation domains. The transduced muFAP-CAR mouse T cells secreted IFN-γ and killed FAP-expressing 3T3 target cells specifically. Adoptively transferred 73.3-FAP-CAR mouse T cells selectively reduced FAPhi stromal cells and inhibited the growth of multiple types of subcutaneously transplanted tumors in wild-type, but not FAP-null immune-competent syngeneic mice. The antitumor effects could be augmented by multiple injections of the CAR T cells, by using CAR T cells with a deficiency in diacylglycerol kinase, or by combination with a vaccine. A major mechanism of action of the muFAP-CAR T cells was the augmentation of the endogenous CD8+ T-cell antitumor responses. Off-tumor toxicity in our models was minimal following muFAP-CAR T-cell therapy. In summary, inhibiting tumor growth by targeting tumor stroma with adoptively transferred CAR T cells directed to FAP can be safe and effective, suggesting that further clinical development of anti-human FAP-CAR is warranted. Cancer Immunol Res; 2(2); 154–66. ©2013 AACR.
Từ khóa
Tài liệu tham khảo
June, 2007, Principles of adoptive T cell cancer therapy, J Clin Invest, 117, 1204, 10.1172/JCI31446
June, 2007, Adoptive T cell therapy for cancer in the clinic, J Clin Invest, 117, 1466, 10.1172/JCI32446
Porter, 2011, Delayed tumor lysis and CLL remission from chimeric antigen receptor-modified T cells, New Engl J Med, 365, 725, 10.1056/NEJMoa1103849
Kalos, 2011, T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia, Sci Trans Med, 3, 95ra73, 10.1126/scitranslmed.3002842
Grupp, 2013, Chimeric antigen receptor-modified T cells for acute lymphoid leukemia, N Engl J Med, 368, 1509, 10.1056/NEJMoa1215134
Jena, 2010, Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor, Blood, 116, 1035, 10.1182/blood-2010-01-043737
Bhowmick, 2004, Stromal fibroblasts in cancer initiation and progression, Nature, 432, 332, 10.1038/nature03096
Orimo, 2005, Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion, Cell, 121, 335, 10.1016/j.cell.2005.02.034
Santos, 2009, Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice, J Clin Invest, 119, 3613, 10.1172/JCI38988
Ito, 2007, The VEGF angiogenic switch of fibroblasts is regulated by MMP-7 from cancer cells, Oncogene, 26, 7194, 10.1038/sj.onc.1210535
Zhang, 2011, Ovarian cancer-associated fibroblasts contribute to epithelial ovarian carcinoma metastasis by promoting angiogenesis, lymphangiogenesis and tumor cell invasion, Cancer Lett, 303, 47, 10.1016/j.canlet.2011.01.011
Fridlender, 2009, Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN, Cancer Cell, 16, 183, 10.1016/j.ccr.2009.06.017
Nazareth, 2007, Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells, J Immunol, 178, 5552, 10.4049/jimmunol.178.9.5552
Cohen, 2008, Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma, Pancreas, 37, 154, 10.1097/MPA.0b013e31816618ce
Goscinsky, 2008, FAP-alpha and uPA show different expression patterns in premalignant and malignant esophageal lesions, Ultrastruct Pathol, 32, 89, 10.1080/01913120802034934
Henry, 2007, Clinical implications of fibroblast activation protein in patients with colon cancer, Clin Cancer Res, 13, 1736, 10.1158/1078-0432.CCR-06-1746
Scanlan, 1994, Molecular cloning of fibroblast activtion proteina, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers, Proc Natl Acad Sci U S A, 91, 5657, 10.1073/pnas.91.12.5657
Garin-Chesa, 1990, Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers, Proc Natl Acad Sci U S A, 87, 7235, 10.1073/pnas.87.18.7235
Niedermeyer, 2001, Expression of the fibroblast activation protein during mouse embryo development, Int J Dev Biol, 45, 445
Mathew, 1995, The gene for fibroblast activation protein [alpha] (FAP), a putative cell surface-bound serine protease expressed in cancer stroma and wound healing, maps to chromosome band 2q23, Genomics, 25, 335, 10.1016/0888-7543(95)80157-H
Wang, 2008, Fibroblast activation protein and chronic liver disease, Front Biosci, 13, 3168, 10.2741/2918
Acharya, 2006, Fibroblast activation protein: a serine protease expressed at the remodeling interface in idiopathic pulmonary fibrosis, Hum Pathol, 37, 352, 10.1016/j.humpath.2005.11.020
Rettig, 1988, Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells, Proc Natl Acad Sci U S A, 85, 3110, 10.1073/pnas.85.9.3110
Huber, 2003, Fibroblast activation protein: differential expression and serine protease activity in reactive stromal fibroblasts of melanocytic skin tumors, J Invest Dermatol, 120, 182, 10.1046/j.1523-1747.2003.12035.x
Aertgeerts, 2005, Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein alpha, J Biol Chem, 280, 19441, 10.1074/jbc.C500092200
Kraman, 2010, Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha, Science, 330, 827, 10.1126/science.1195300
Roberts, 2013, Depletion of stromal cells expressing fibroblast activation protein-a from skeletal muscle and bone marrow results in cachexia and anemia, J Exp Med, 210, 1137, 10.1084/jem.20122344
Loeffler, 2006, Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake, J Clin Invest, 116, 1955, 10.1172/JCI26532
Lee, 2005, Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts, Cancer Res, 65, 11156, 10.1158/0008-5472.CAN-05-2805
Ostermann, 2008, Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts, Clin Cancer Res, 14, 4584, 10.1158/1078-0432.CCR-07-5211
Tran, 2013, Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia, J Exp Med, 210, 1125, 10.1084/jem.20130110
Lee, 1999, Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients, Nat Med, 5, 677, 10.1038/9525
Kakarla, 2013, Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma, Mol Ther, 21, 1611, 10.1038/mt.2013.110
Schuberth, 2013, Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells, J Transl Med, 11, 187, 10.1186/1479-5876-11-187
Liu, 2012, Fibroblast activation protein: a potential therapeutic target in cancer, Cancer Biol Ther, 13, 123, 10.4161/cbt.13.3.18696
Jackaman, 2003, IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2, J Immunol, 171, 5051, 10.4049/jimmunol.171.10.5051
Lin, 1996, Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen, Cancer Res, 56, 21
Johnson, 2001, Somatic activation of the K-ras oncogene causes early onset lung cancer in mice, Nature, 410, 1111, 10.1038/35074129
Niedermeyer, 2000, Targeted disruption of mouse fibroblast activation protein, Mol Cell Biol, 20, 1089, 10.1128/MCB.20.3.1089-1094.2000
Milone, 2009, Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo, Mol Ther, 17, 1453, 10.1038/mt.2009.83
Pear, 1998, Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow, Blood, 92, 3780, 10.1182/blood.V92.10.3780
Morgan, 2012, Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma, Hum Gene Ther, 23, 1043, 10.1089/hum.2012.041
Riese, 2013, Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases, Cancer Res, 73, 3566, 10.1158/0008-5472.CAN-12-3874
Moon, 2011, Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor, Clin Cancer Res, 17, 4719, 10.1158/1078-0432.CCR-11-0351
Peng, 2012, PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines, Cancer Res, 72, 5209, 10.1158/0008-5472.CAN-12-1187
Chinnasamy, 2013, Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice, Cancer Res, 73, 3371, 10.1158/0008-5472.CAN-12-3913
Muranski, 2006, Increased intensity lymphodepletion and adoptive immunotherapy-how far can we go?, Nat Clin Pract Oncol, 3, 668, 10.1038/ncponc0666
Scott, 2003, A phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer, Clin Cancer Res, 9, 1639
Hombach, 2007, T cell activation by antibody-like immunoreceptors: the position of the binding epitope within the target molecule determines the efficiency of activation of redirected T cells, J Immunol, 178, 4650, 10.4049/jimmunol.178.7.4650